Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal decision profile

Cancer Treatment and Research Communications

Medicine · Biochemistry, Genetics and Molecular Biology
Elsevier BVUnited StatespISSN 2468-2942eISSN 2468-2942
Checking system sharing availability.Visit homepage
Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
1.3

Journal Metrics Score 2026 · 2021–2024 window citedness 2.96.

Submission-to-acceptance
i
Submission-to-acceptanceCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
129 daysmedian

Middle 50%: 53–221 days

100 of 100 PubMed-indexed articles · 100% coverage · 2024–2025

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
$2,050

Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
1.32026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#312 / 1,448LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
10.8%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
0.70MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
129 daysIQR 53–221 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
137 / yr2021–2024 AVG
Field-normalized top 10% share10.8%

59 of 547 works · same type, year & subfield

Field-normalized top 1% share1.6%

9 works · same type, year & subfield

Median FWCI0.70×

Below field-year expectation

Source output rank#312

of 1,448 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.70, so its typical recent paper runs about 30% below its field benchmark.

What does Top 10% Share mean?

10.8% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

362016
342017
262018
302019
1342020
1972021
1672022
1022023
812024
2102025

Recent work-type mix

547 OpenAlex works · 2021–2024

Article93.4%
Review4.4%
Erratum1.1%
Retraction1.1%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works
Lung NeoplasmsCarcinoma, Non-Small-Cell LungBreast NeoplasmsColorectal NeoplasmsNeoplasmsUterine Cervical NeoplasmsAntineoplastic AgentsProstatic NeoplasmsAdenocarcinoma

Leading OpenAlex topics

2021–2024 works
Lung Cancer Treatments and Mutations42
Cancer Immunotherapy and Biomarkers33
Breast Cancer Treatment Studies21
Lung Cancer Diagnosis and Treatment20
Cancer Genomics and Diagnostics14
Endometrial and Cervical Cancer Treatments12
Colorectal Cancer Treatments and Studies11
Cholangiocarcinoma and Gallbladder Cancer Studies10
Inflammatory Biomarkers in Disease Prognosis10
Multiple Myeloma Research and Treatments10
Methodology: OpenAlex snapshot 2026-08-12. FWCI, percentile badges, topics, and type mix use 547 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Recommended alternatives

Candidates share the leading OpenAlex topic, then subfield or field when needed, and are ranked by current Journal Metrics Score.

OpenAlex topic-neighbor model · Preview
Lancet OncologyTopic-neighbor alternative11.3Metrics Score—Submission → acceptance$$$Cost*Journal of Cancer Research and Clinical OncologyTopic-neighbor alternative4.7Metrics Score48dIQR 33–97dSubmission → acceptance$$$Cost*Targeted OncologyTopic-neighbor alternative4.6Metrics Score—Submission → acceptance$$$Cost*OncologistTopic-neighbor alternative3.2Metrics Score—Submission → acceptance$$Cost*Cancer Research and TreatmentTopic-neighbor alternative3.0Metrics Score101dIQR 74–131dSubmission → acceptance$—Cost*Clinical Medicine Insights-OncologyTopic-neighbor alternative2.8Metrics Score—Submission → acceptance$$Cost*

More alternative journals

Expert Review of Anticancer TherapyFuture OncologyLung Cancer-Targets and TherapyClinical Lung CancerTranslational Lung Cancer ResearchOncology and Therapy

* Cost is indicative only. APCs, taxes, waivers, and member discounts can change—always verify on the journal's official website.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
Pulmonary and Respiratory MedicineQ3
OncologyQ3

Considering submitting to Cancer Treatment and Research Communications?

Use your manuscript title to find AI-ranked journals with related recent work, fit reasons, risks, and submission strategy.

Match my manuscript →
Q3
Subfield Quartile
B4
CAS Block

Ranking and source check

#619
of 853 Oncology field journals
#61
among Q3 Oncology journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

View all Oncology journals →View Q1 Oncology journals →

Journal Details

OpenAlex Works
1,284
H-Index
38
Fully Open Access
Yes
Recent OA Works
1,183
Subject Areas
Pulmonary and Respiratory MedicinePulmonary and Respiratory MedicineOncologyOncology

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

Related Guides

Field Rankings
Best Oncology Journals: Journal Metrics Scores and Cancer Research Guide
12 min read
Field Rankings
Archived Medical Journal Selection Guide
14 min read
Publishing Guide
How to Choose the Right Journal for Your Research Paper
15 min read
Publishing Guide
Journal Selection Criteria: Essential Factors for Choosing the Right Publication Venue
20 min read
Back to Search